CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Impact · against what's priced in

The article provides no new catalysts for CRSP, as the consensus revenue and EPS projections are already accounted for in the market's current valuation. The stock's recent underperformance reflects a lack of confidence in short-term trends rather than any shift in the fundamental assumptions regarding its pipeline or cash position.

CRSP+0.00

Already priced in

The price assumes

the approved CASGEVY therapy and its 500+ initiated patients, though the price discounts the two-to-three quarter lag before that translates into revenue